Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: Proposal of a unified hypothesis

Cancer Investigation

Volumn 24, Issue 8, 2006, Pages 754-779

  Dorai, Thambi ^a   Sawczuk, Ihor ^b   Pastorek, Jaromir ^c   Wiernik, Peter H ^a   Dutcher, Janice P ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

Birt Hogg Dube; c Met; Carbonic anhydrases; Chromophobe; Clear cell; Fumarate hydratase; Oncocytoma; Papillary type 1; Papillary type 2; Renal cell carcinoma; Succinate dehydrogenase Tuberous Sclerosis; VHL

Indexed keywords

CARBONATE DEHYDRATASE; TYROSINE KINASE RECEPTOR;

BIRT HOGG DUBE SYNDROME; CANCER CLASSIFICATION; CANCER GROWTH; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLEAR CELL CARCINOMA; ENZYME ACTIVITY; HISTOPATHOLOGY; HUMAN; HYPOTHESIS; HYPOXIA; KIDNEY CARCINOMA; MOLECULAR BIOLOGY; MOLECULAR SYSTEMATICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; GLYCOLYSIS; HUMANS; KIDNEY NEOPLASMS;

EID: 33845654683     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900601062321     Document Type: Review

References (163)

1. Hock, L.M.; Lynch, J.; Balaji, K.C. Increasing incidence of all stages of kidney cancer in the last two decades in the United states: an analysis of surveillance, epidemiology and end results program data. J. Urol. 2002, 167, 57-60.
2. Jemal, A.; Murray, T.; Samuels, A.; et al. Cancer Statistics 2003. Cancer J. Clin. 2003, 52, 23-47.
3. Linehan, W.M.; Walther, M.M.; Zbar, B. The genetic basis of the cancer of the kidney. J. Urol. 2003, 170, 2163-2172.
4. Linehan, W.M.; Zbar, B.; Kluasner, R.D. Renal carcinoma: In The Genetic Basis of Human Cancer, 2nd ed. Vogelstein, B.; Kinzler, K.W. Eds. McGraw Hill, New York, 2002,
5. Reuter, V.E.; Presti, J.C., Jr. Contemporary approach to the classification of renal epithelial tumors. Semin. Oncol. 2000, 27, 124-137.
6. Lam, J.S.; Belldegrun, A.S.; Figlin, R.A. Tissue array based predictions of pathobiology, prognosis and response to treatment for renal cell carcinoma therapy. Clin. Cancer Res. 2004, 10, 6304S-6309S.
7. Lam, J.S.; Leppert, J.T.; Figlin, R.A.; Belldegrun, A.S. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 2005, 66(5Suppl), 1-9.
8. Tan, M.H.; Rogers, C.G.; Cooper, J.T.; et al. The B.T. gene expression profiling of renal cell carcinoma. Clin. Cancer Res. 2004, 10, 6315s-6321s.
9. Takahashi, M.; Yang, X.J.; Sugimura, J.; et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene. 2003, 22, 6810-6818.
10. Sweeney, P.; El-Naggar, A.K.; Lin, S.H.; Pisters, L.L. Biological significance of c-met overexpression in papillary renal cell carcinoma. J. Urol. 2002, 168, 51-55.
11. Lubensky, I.A.; Schmidt, L.; Zhuang, Z.; et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am. J. Pathol. 1999, 155, 517-526.
12. Iliopoulos, O.; Eng, C. Genetic and clinical aspects of familial renal neoplasms. Semin. Oncol. 2000, 27, 138-149.
13. McManus, E.J.; Alessi, D.R. TSC1-TSC2: a complex tale of PKB mediated S6K regulation. Nature Cell Biol. 2002, 4, E214-E216.
14. 2 sensing. Science. 2001, 292, 464-468.
15. 2 regulated prolyl hydroxylation. Science. 2001, 292, 468-472.
16. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer. 2003, 3, 721-732.
17. Pantuck, A.J.; Zeng, G.; Belldegrun, A.S.; Figlin, R.A. Pathobiology, prognosis and targeted therapy for renal cell carcinoma exploiting hypoxia induced pathway. Clin. Cancer Res. 2003, 9, 4641-4652.
18. Parkkila, S. An overview of the distribution and function of carbonic anhydrases in mammals. In The Carbonic Anhydrases: New horizons. Chegwidden, W.R.; Carter, N.; Edwards, Y.; Eds. Birkhauser Verlag, Basel, Switzerland, 2000, pp76-93.
19. Pastorekova, S.; Parkkila, S.; Pastorek, J.; Supuran, CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem. 2004, 19, 199-229.
20. Hilvo, M.; Tolvanen, M.; Clark, A.; et al. Characterization of CA XV, a new GPI-anchored form of carbonic anhydrase. Biochem. J. 2005, 392(Pt1), 83-92.
21. Dodgson, S.J.; Cherian, K. Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis. Am. J. Physiol. 1989, 257, E791-E796.
22. Tolar, J.; Teitelbaum, S.L.; Orchard, P.J. Osteopetrosis. New Eng. J. Med. 2004, 351, 2839-2849.
23. Sly, W.S.; Hu, P.Y. The carbonic anhydrase II deficiency syndrome: Osteopetrosis with renal tubular acidosis and cerebral calcification. In The Molecular and Metaboloic Bases of Inherited Disease. Scriver, C.R.; Beaudet, A.L.; Sly, W.S.; Valle, D. Eds. Pp 4113-4124. McGraw-Hill New York. 1995.
24. Sly, W.S.; Hu, P.Y. Human carbonic anhydrases and carbonic anhydrase deficiencies. Ann. Rev. Biochem. 1995, 64, 375-401.
25. Potter, C.; Harris, A.L. Hypoxia inducible carbonic anhydrase IX: Marker for tumor hypoxia, survival pathway and therapy. Cell Cycle. 2004, 3, 164-167.
26. Parkkila, S.; Parkkila, A.K.; Saarino, J.; et al. Expression of membrane associated carbonic anhydrase isoenzyme XII in the human kidney and renal tumors. J. Histochem. Cytochem. 2000, 48, 1601-1608.
27. Olive, P.L.; Aquino-Parsons, C.; Macphail, S.H.; et al. Carbonic anhydrase IX as an endogeneous marker for hypoxic cells in cervical cancer. Cancer Res. 2001, 61, 8924-8929.
28. Richard, D.E.; Berra, E, Pouysegur, J. Nonhypoxic pathway mediates the induction of hypoxia inducible factor -1 α in vascular smooth muscle cells. J. Biol. Chem. 2000, 275, 26765-26771.
29. Kaluz, S.; Kaluzova, M.; Chrastina, A.; et al. Lowered oxygen tension induces expression of hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia inducible factor 1 alpha stabilization: a role for phosphatidyl inositol-3-Kinase. Cancer Res. 2002, 62, 4469-4477.
30. Leek, R.D.; Landers, R.J.; Harris, A.L.; Lewis, C.E. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Brit. J. Cancer. 1999, 79, 991-995.
31. Haddad, J.J.; Land, S.C. A non-hypoxic ROS-sensitive pathway mediates TNF-alpha dependent regulation of HIF-1 alpha. FEBS Lett. 2001, 505, 269-274.
32. Cho, M.; Uemura, S.; Kim, S.C.; et al. Hypomethylation of the MN/CA9 promoter and upregulation of MN/CA9 expression in human renal cell carcinoma. Brit. J. Cancer. 2001, 85, 563-567.
33. Rafajova, M.; Zatovicova, M.; Kettmann, R.; Pastorek, J.; Pastorekova, S.; Induction by hypoxia combined with low glucose or bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int. J. Oncol. 2004, 24, 995-1004.
34. Kietzmann, T.; Krones-Herzig, A.; Jungermann, K. Signaling cross talk between hypoxia and glucose via hypoxia inducible factor-1 and glucose response elements. Biochem. Pharmacol. 2002, 64, 903-911.
35. Gatenby, R.A.; Gillies, R.J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer. 2004, 4, 891-899.
36. Baudelet, C.; Ansiaux, R.; Jordan, B.F.; Havaux, X.; Macq, B.; Gallez, B. Physiological noise in murine solid tumors using T2* weighted gradient echo imaging: a marker for acute tumor hypoxia? Phys. Med. Biol. 2004, 49, 3389-3411.
37. Graeber, T.G.; Osmanian, C.; Jacks, T.; et al. Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumors. Nature. 1996, 329, 88-91.
38. Martinez-Zaguilan, R.; Seftor, E.A.; Sefor, R.E.; et al. Acidic pH enhances the invasive behavior of human melanoma cells. Clin. Exp. Metastasis. 1996, 14, 176-186.
39. Brand, K. Aerobic glycolysis by proliferating cells: protection against oxidative stress at the expense of energy yield. J. Bioener. Biomemb. 1997, 29, 355-364.
40. Park, H.J.; Lyons, J.C.; Ohtsubo, T.; Song, C.W. Acidic environment causes apoptosis by increasing caspase activity. Brit. J. Cancer. 1999, 80, 1892-1897.
41. McLean, L.A.; Roscoe, J.; Jorgensen, N.K.; Gorin, F.A.; Cala, P.M. Malignant gliomas display altred pH regulation by NHE1 compared with nontrnsformed astrocytes. Am J Physiol. 2000, 278, C676-C688.
42. Martinez-Zaguilan, R.; Lynch, R.M.; Martinez, G.M. and Gillies, R.J. Vacuolar type ATPases are functionally expressed in the plasma membranes of human tumor cells. Am. J. Physiol. 1993, 265, c1015-c1029.
43. Morgan, P.E.; Pastorekova, S.; Casey, J.R. Functional and physical interaction between bicarbonate transport proteins and the transmembrane carbonic anhydrase, CA IX. XXV International Congress of Physiological Sciences, March 31-April 5, San Diego, CA, Abstract No 366.5.
44. Karumanchi, S.A.; Jiang, L.; Knebelmann, B.; et al.. VHL tumor suppressor regulates Cl/HCO3- exchange and Na+/H+ exchange activities in renal carcinoma cells. Physiol. Genomics. 2001, 5, 119-128.
45. Sterling, D.; Brown, N.J.; Supuran, C.T.; Casey, J.R. The functional and physical relationship between the DRA bicarbonate transporter and carbonic anhydrase II. Am. J. Physiol. Cell Physiol. 2002, 283, C1522-C1529.
46. Williams, A.C.; Collard, T.J.; Paraskeva, C. An acidic environment leads to p53 dependent induction of apoptosis. Oncogene. 1999, 18, 3199-3204.
47. Shi, Q.; Le, X.; Wang, B.; Abbruzzese, J.L.; Xiong, Q.; He, Y.; Xie, K. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene. 2001, 20, 3751-3756.
48. Rohzin, J.; Sameni, M.; Ziegler, G.; Sloane, B.F. Pericellular pH affects distribution and secretion of cathepsinB in malignant cells. Cancer Res. 1994, 54, 6517-6525.
49. Lardner, A. The effects of extracellular pH on immune function. Leukocyte Biol. 2001, 69, 522-530.
50. Morita, T.; Nagaki, T.; Fukuda, I.; Okumura, K. Clastogenicity of low pH to various cultured mammalian cells. Mutation Res. 1992, 268, 297-305.
51. Schlappack, O.K.; Zimmermann, A.; Hill, R.P. Glucose starvation and acidosis: effect on experimental metastatic potential, DNA content and MTX resistance ofmurine tumor cells. Brit. J. Cancer. 1994, 64, 6517-6525.
52. Lynch, C.J.; Fox, H.; Hazen, S.A.; et al. Role of hepatic carbonic anhydrase in de novo lipogenesis. Biochem. J. 1995, 310, 197-202.
53. Scharfe, T.; Storkel, S.; Yokoyama, M.; et al. Tumor specific antigen for human renal cell carcinoma: ultrastructural localization of the antigen by immunoelectron microscopy. Eur. Urol. 1988, 14, 464-469.
54. Potter, C.P.S.; Harris, A.L. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Brit. J. Cancer. 2003, 89, 2-7.
55. Yamagata, M.; Hasuda, K.; Stamato, T.; Tannock, I.F. The contribution of lactic acid to acidification of tumors: studies on variant cells lacking lactate dehydrogenase. Brit. J. Cancer. 1998, 77, 1726-1731.
56. Svastova, E.; Hulikova, A.; Rafajova, M.; et al. Hypoxia activates the capacity of tumor associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004, 577, 439-445.
57. Svastova, E.; Zilka, N.; Zatovicova, M.; et al. Carbonic anhydrase IX reduces E-cadherin mediated adhesion of MDCK cells via interaction with beta-catenin. Exp. Cell Res. 2003, 290, 332-345.
58. Dorai, T. Expression of CA IX in exosomal vesicles from renal carcinoma cells. (manuscript in preparation)
59. Thery, C.; Zitvogel, L.; Amigorena, S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2, 569-579.
60. Angelucci, A.; D'Ascenzo, S.; Festuccia, C.; et al. Vesicle associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clin. Exp. Metastasis. 2000, 18, 163-170.
61. Dorai, T.; Sawczuk, I.S.; Pastorek, J.; et al. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur. J. Cancer. 2005, 41, 2935-2947.
62. Cherukuri, A.; Dykstra, M.; Pierce, S.K. Floating the raft hypothesis: Lipid rafts play a role in immune cell activation. Immunity. 2001, 14, 657-660.
63. Satoh, M.; Nejad, F.M.; Ohtani, H.; et al. Association of renal cell carcinoma antigen, disialylgalactosylgloboside with c-src and RhoA in clustered domains at the cell membrane. Int. J. Oncol. 2000, 16, 529-536.
64. Uhlman, D.L.; Nguyen, P.; Manivel, J.C.; et al. Epidermal growth factor receptor and transforming growth factor α expression in papillary and non-papillary renal cell carcinoma: Correlation with metastatic behavior and prognosis. Clin. Cancer Res. 1995, 1, 913-920.
65. Ramp, U.; Jaquet, K.; Reinecke, P.; et al. Functional intactness of stimulatory and inhibitory autocrine loops in human renal cell carcinoma cell lines of the clear cell type. J. Urol. 1997, 157, 2345-2350.
66. Scher, H.I.; Sarkis, A.; Reuter, V.; et al. Changing patterns of expression of the epidermal growth factor receptor and transforming growth factor-alpha in the progression of prostatic neoplasms. Clin. Cancer Res. 1995, 1, 545-550.
67. Nanjundan, M.; Sun, J.; Zhao, J.; et al. Plasma membrane phospholipids scramblase 1 promotes EGF-dependent activation of c-src through the epidermal growth factor receptor. J. Biol. Chem. 2003, 278, 37413-37418.
68. Chen, X.; Resh, M.D. Cholesterol depletion from plasma membrane triggers ligand independent activation of the epidermal growth factor receptor. J. Biol. Chem. 2002, 277, 49631-49637.
69. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell. 2000, 103, 211-225.
70. Vogt, P.K. PI-3 Kinase, mTOR, protein synthesis and cancer. Trends Mol. Med. 2001, 7, 482-484.
71. Aoki, M.; Blazek, E.; Vogt, P.K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins PI-3K and AKT. Proc. Natl. Acad. Sci. USA. 2001, 98, 136-141.
72. Bjornsti, M.A.; Houghton, P.J. The mTOR pathway: a target for cancer therapy. Nature Rev. Cancer. 2004, 4, 335-348.
73. Page, E.L.; Robitaille, G.A.; Pouyssegur, J.; Richard, D.E. Induction of hypoxia inducible factor 1-α by transcriptional and translational mechanisms. J. Biol. Chem. 2002, 277, 48403-48409.
74. Maxwell, P.H.; Wiesener, M.S.; Chang, G.W.; et al. The tumor suppressor protein VHL targets hypoxia inducible factors for oxygen dependent proteolysis. Nature. 1999, 399, 271-275.
75. Ivanov, S.V.; Kuzmin, I.; Wei, M.H.; et al. Down regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild type von Hippel Lindau transgenes. Proc. Natl. Acad. Sci. USA. 1998, 95, 12596-12601.
76. Mekhail, K.; Gunaratnam, L.; Bonicalzi, M.E.; Lee, S. HIF activation by pH dependent nucleolar sequestration of VHL. Nature Cell Biol. 2004, 6, 642-647.
77. Perera, A.D.; Kleymenova, E.V.; Walker, C.L. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma. Clin. Cancer Res. 2000, 6, 1518-1523.
78. Knebelmann, B.; Ananth, S.; Cohen, H.T.; Sukhatme, V.P. Transforming growth factor α is a target for the von Hippel-Lindau tumor suppressor. Cancer Res. 1998, 58, 226-231.
79. Pal, S.; Claffey, K.P.; Dvora, K.H.F.; Mukhopadhyay, D. The von hippel-Lindau gene product inhibits vascular permeability factor/ vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J. Biol. Chem. 1997, 272, 27509-27512.
80. Kawakami, Y.; Nishimato, H.; Kitaura, J.; et al. Protein Kinase C beta II regulates Akt phosphorylation on ser 473 in a cell type and stimulus specific fashion. J. Biol. Chem. 2004, 279, 47720-47725.
81. Los, M.; Zeamari, S.; Foekens, J.A.; Gebbin, K.M.F.; Voest, E.E. Regulation of the urokinase activator system by the von Hippel-Lindau tumor suppressor gene. Cancer Res. 1999, 59, 4440-4445.
82. Zatovicova, M.; Sedlakova, O.; Svastova, E.; et al. Ectodomain shedding of the hypoxia induced carbonic anhydrase IX is a metalloprotease dependent process regulated by TACE/ADAM-17. Brit. J. Cancer. 2005, 93, 1267-1276.
83. Tureci, O.; Sahin, U.; Vollmar, E.; et al. Human carbonic anhydrase XII: cDNA cloning, expression and chromosomal localization of a carbonic anhydarse gene that is overexpressed in some renal tumors. Proc. Natl. Acad. Sci. USA. 1998, 95, 7608-7613.
84. Watson, P.H.; Chia, S.K.; Wykoff, C.C.; et al. Carbonic anhydarse XII is a marker of good prognosis in invasive breast carcinoma. Brit. J. Cancer. 2003, 88, 1065-1070.
85. Kopacek, J.; Barathova, M.; Dequiedt, F.; et al. MAPK pathway contributes to density and hypoxia induced expression of tumor associated carbonic anhydrase IX. Biochim. Biophys. Acta. 2005, 1729, 41-49.
86. Bartosova, M.; Parkkila, S.; Pohlodek, K.; et al. Expression of carbonic anhydrase IX in breast ia associated with malignant tissues and is related to the expression of c-erbB2. J. Pathol. 2002, 197, 314-321.
87. Stum, G.; Eberwein, S.; Rostock-Wolf, et al. Concomitant overxepression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int. J. Cancer. 1996, 69, 17-22.
88. Vullo, D.; Franchi, N.M.; Gallori, E.; et al. Carbonic anhydrase inhibitors: inhibition of tumor associated isoenzyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 2003, 13, 1005-1009.
89. Pastorekova, S.; Casini, A.; Scozzafava, A.; Vullo, D.; Pastorek, J.; Supuran, C.T. Carbonic anhydrase inhibitors: the first selective membrane impermeant inhibitors targeting the tumor associated isoenzyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 869-873.
90. Atkins, M.B.; Regan, M.; McDermott, D. Update on the role of interleukin-2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin. Cancer Res. 2004(suppl), 10, 6342s-6346s.
91. Velikovic, M.; Delahunt, B.; McIver, B.; Grebe, S.K. Intragenic PTEN/MMAC-1 loss of heterozygosity in conventional (clear cell) renal cell carcinoma is associated with poor patient prognosis. Mod. Pathol. 2002, 15, 479-485.
92. Kim, H.L.; Seligson, D.; Liu, X.; et al. Using protein expressions to predict the survival in clear cell carcinoma. Clin. Cancer Res. 2004, 10, 5464-5471.
93. Schmidt, L.; Junker, K.; Nakaigawa, N.; et al. Novel mutations of the met protooncogene in papillary renal cell carcinoma. Oncogene. 1999, 18, 2343-2350.
94. Stadler, W.M. Therapeutic options for variant renal cancer: a true orphan disease. Clin. Cancer Res. 2004, 10, 6393s-6396s.
95. Weidner, K.M.; Sachs, M.; Birchmeier, W. The met receptor tyrosine kinase transduces motility, proliferation and morphonenetic signals of scatter factor/hepatocyte growth factor in epithelial cells. J. Cell Biol. 1993, 121, 145-154.
96. Kuure, S.; Vuolteenaho, R.; Vainio, S. Kidney morphogenesis: cellular and molecular regulation. Mech. Dev. 2000, 92, 31-45.
97. Savagner, P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays. 2001, 23, 912-923.
98. Thiery, J.P. Epithelial-mesenchymal transitions in tumor progression. Nat. Rev. Cancer. 2002, 2, 442-454.
99. Furge, K.A.; Zhang, Y.W.; Vande Woude, G.F. Met receptor tyrosine kinase: enhanced signaling through adaptor proteins. Oncogene. 2000, 19, 5582-5589.
100. Hirohashi, S. Inactivation of E-cadherin mediated cell adhesion system in human cancers. Am. J. Pathol. 1998, 153, 333-339.
101. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Vande Woude, G.F. Met, metastasis, motility and more. Nature Rev. Mol. Cell Biol. 2003, 4, 915-925.
102. Eger, A.; Stockinger, A.; Schaffhauser, B.; Beug, H.; Foisner, R. Epithelial mesenchymal transition by c-fos estrogen receptor activation involves nuclear translocation of beta-catenin and upregulation of beta- catenin/lymphoid enhancer binding factor-1 transcriptional activity. J. Cell Biol. 2000, 148, 173-188.
103. Morali, O.G.; Delmar, V.; Moore, R.; Jeanney, C.; Thiery, J.P.; Larue, L. IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene. 2001, 20, 4942-4950.
104. Wykoff, C.C.; Beasley, N.J.; Watson, P.H.; et al. Hypoxia inducible expression of tumor associated carbonic anhydrases. Cancer Res. 2000, 60, 7075-7083.
105. Zisman, A.; Pantuck, A.J.; Bui MHT, et al. LABAZ1: a metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen. Cancer Res. 2003, 63, 4952-4959.
106. Linehan, W.M. , Vasselli, J.; Srinivasan, R.; et al. Genetic basis of the cancer of the kidney: Disease specific approaches to therapy. Clin. Cancer Res. 2004, 10, 6282s-6289s.
107. Maulik, G.; Madhiwala, P.; Brooks, S.; et al. Activated c-Met signals through PI-3 Kinase with dramatic effects on cytoskeletal functions in small cell lung cancer. J. Cell. Mol. Med. 2002, 6, 539-553.
108. Nakamura, T.; Kanda, S.; Yamamoto, K; et al. Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through PI-3 Kinase activation. Oncogene. 2001, 20, 7610-7623.
109. Schwab, A. Functional and spatial distribution of ion channels and transporters in cell migration. Am. J. Physiol. Renal. Physiol. 2001, 280, F739-F747.
110. Monga, S.P.S.; Mars, W.M.; Pediatitakis, P.; et al. Hepatocyte growth factor induces Wnt-independenmt nuclear translocation of beta- catenin after met-beta-catenin dissociation in hepatocytes. Cancer Res. 2002, 62, 2064-2071.
111. Pennacchietti, S.; Michieli, P.; Galluzzo, M.; et al. Hypoxia promotes invasive growth by transcriptional activation of the met proto-oncogene. Cancer Cell. 2003, 3, 347-361.
112. Boccaccio, C.; Gaudino, G.; Gambarotta, G.; Galini, F.; Comoglio, P.M. Hepatocyte growth factor (HGF) receptor expressiuon is inducible and is part of the delayed-early response to HGF. J. Biol. Chem. 1994, 269, 12846-12851.
113. Tacchini, L.; Dausi, P, Matteucci, E.; Desiderio, M.A. Hepatocyte growth factor signaling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis. 2001, 22, 1363-1371.
114. Koochekpour, S.; Jeffers, M.; Wang, P.H.; et al. The von Hippel Lindau tumor suppressor gene inhibits hepatocyte growth factor/ scatter factor induced invasion and branching morphogenesis in renal carcinoma cells. Mol. Cell Biol. 1999, 19, 5902-5912.
115. Oh, Rr; Park, J.Y.; Lee, J.H.; et al. Expression of HGF/SF and met proteins is associated with genetic alterations of VHL gene in primary renal cell carcinomas. APMIS. 2002, 110, 229-238.
116. Abounader, R.; Reznik, T.; Colantuoni, C.; et al. Regulation of c-met dependent gene expression by PTEN. Oncogene. 2004, 23, 9173-9182.
117. Alam, N.A.; Rowan, A.J.; Wortham, N.C.; et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cencer, and fumarate hydratase deficiency. Human Mol. Genet. 2003, 12, 1241-1252.
118. Tomlinson, I.P.; Alam, N.A.; Rowan, A.J.; et al Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cancer. Nat. Genet. 2002, 30, 406-410.
119. Baysal, B.E.; Ferrell, R.E.; Willett-Brozick, J.E.; et al. Mutations in SDHD, a mitochondrial complex II gene in hereditary paragnaglioma. Science. 2000, 287, 858-851.
120. Astuti, D.; Latif, F.; Dallol, A.; et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibitlity to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet. 2001, 69, 49-54.
121. Paddenberg, R.; Ishaq, B.; Goldenberg, A.; et al. Essential role of complex II of the respiratory chain in hypoxia induced ROS generation in the pulmonary vasculature. Am. J. Physiol. Lung Cell Mol. Physiol. 2003, 284, L710-L719.
122. Bourgeron, T.; Chretien, D.; Poggi-Bach, J.; et al. Mutation of the fumarase gene in two siblings with progressive encephalopathy and fumarase deficiency. J. Clin. Invest. 1994, 93, 2514-2518.
123. Oberley, L.W. Anticancer therapy by overexpression of superoxide dismuatse. Antioxid Redox Signal. 2001, 3, 461-472.
124. Pollard, P.J.; Briere, J.J.; Alam, N.A.; et al. Accumulation of Krebs cycle intermediates and overexpression of HIF1α in tumors which result from germline FH and SDH mutations. Human Mol. Genet. 2005, 14, 2231-2239.
125. Selak, M.A.; Armour, S.M.; Mackenzie, E.D.; et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-1 prolylhydroxylase. Cancer Cell. 2005, 7, 77-85.
126. Isaacs, J.S.; Jung, Y.J.; Mole, D.R.; et al. HIF overexpression correlates with bialleleic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005, 8, 143-153.
127. Malaisse, W.J.; Zhang, T.M.; Verbruggen, I.; Willem, R. D-glucose generation from 2-13C pyruvate in hepatocytes: implications in terms of enzyme-to-enzyme chanelling. Arch. Biochem. Biophys. 1996, 332, 341-351.
128. Rose, I.A. How fumarase recycles after malate - fumarate reaction: insights into the reaction mechanism. Biochemistry. 1998, 37, 17651-17658.
129. Baysal, B.E. Krebs cycle enzymes as tumor suppressors. Drug Disc. Today Dis. Mech. 2005, 2, 247-254.
130. Shen-Ong, G.L.; Feng, Y.; Troyer, D.A. Expression profiling identifies a novel alpha methyl acyl racemase exon with fumarate hydratase homology. Cancer Res. 2003, 63, 3296-3301.
131. Lopez-Barneo, J.; Pardol, R.; Ortega-Saez, P. Cellular mechanism of oxygen sensing. Ann. Rev. Physiol. 2001, 63, 259-287.
132. Williamson, J.R.; Chang, K.; Frango, S.M.; et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes. 1993, 42, 801-813.
133. Scozzafava, A.; Supuran, C.T. Carbonic anhydrase activators: human isoenzyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1. Bioorg. Med. Chem. Lett. 2002, 12, 1177-1180.
134. Supuran, C.T.; Vullo Dmanole, G.; Casini, A.; Scozzafava, A. Designing of novel carbonic anhydrase inhibitors and activators. Curr. Med. Chem. Cardiovasc. Hematol. Agents. 2004, 2, 49-68.
135. Horiuchi, A.; Nikaido, T.; Taniguchi, S.; Fujii, S. Possible role of calphonin h1 as a tumor suppressor in human uterine leiomyoma. J. Natl. Cancer Inst. 1999, 91, 790-796.
136. Brusilow, S.W.; Horwich, A.L. In Urea cycle enzymes 8th edition, pp 1948-1949. McGraw-Hill, New York, 2001.
137. Mak, B.C.; Yeung, R.S. The tuberous sclerosis complex genes in tumor development. Cancer Investig. 2004, 22, 588-603.
138. Tee, A.R.; Blenis, J. mTOR, translational control and human disease. Semin. Cell. Dev. Biol. 2005, 16, 29-37.
139. Mak, B.C.; Takemaru, K.; Kenerson, H.L.; Moon, R.T.; Yeung, R.S. The tuberin-hamartin complex negatively regulates beta-catenin signaling activity. J. Biol. Chem. 2003, 278, 5947-5951.
140. Shaw, R.J.; Bardeesy, N.; Manning, B.D.; et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004, 6, 91-99.
141. Inoki, K.; Li, Y.; Zhu, T.; Wu, J.; Guan, K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat. Cell Biol. 2002, 4, 648-657.
142. Brugarolas, J.B.; Vazquez, F.; Reddy, A.; Sellers, W.R.; Kaelin, Jr., W.G. TSC2 regulates VEGF through mTOR-dependent and - independent pathways. Cancer Cell. 2003, 4, 147-158.
143. El-Hashemite, N.; Walker, V.; Zhang, H.; Kwiatkowski, D.J. Loss of TSC1 and TSC2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res. 2003, 63, 5173-5177.
144. Maity, A.; Pore, N.; Lee, J.; Solomon, D.; O'Rourke, D.M. Epidermal growth factor receptor transcriptionally upregulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol-3′-Kinase and distinct from that induced by hypoxia. Cancer Res. 2000, 60, 5879-5886.
145. Pavlovich, C.P.; Walther, M.M.; Eyler, R.A.; et al. Renal tumors in the Birt-Hogg-Dube syndrome. Am. J. Surg. Pathol. 2002, 26, 1542-1552.
146. Toro, J.; Glenn, G.; Duray, P.; et al. Birt-Hogg-Dube syndrome: a novel marker for kidney neoplasia. Arch. Dermatol. 1999, 135, 1195-1202.
147. Nickerson, M.L.; Warren, M.B.; Toro, J.R.; et al. Mutations in a novel gene lead to kidney tumors, lung wall effects, and benign tumors of the hair follicle in patients with Birt-Hogg-Dube syndrome. Cancer Cell. 2002, 2, 157-164.
148. Uno, F.; Sasaki, J.; Nishizaki, M.; et al. Myristoylation of the fus1 protein is required for tumor suppression in lung cancer cells. Cancer Res. 2004, 64, 2969-2976.
149. Ames, J.B.; Tanaka, T.; Stryer, L.; Ikura, M. Portrait of a myristoyl switch protein. Curr. Opin. Struct. Biol. 1996, 6, 432-438.
150. Ames, J.B.; Ishima, R, Tanaka, T.; Gordon, J.I.; Stryer, L.; Ikura, M. Molecular mechanics of calcium-myristoyl switches. Nature (Lond). 1997, 389, 198-202.
151. Resh, M.D. Fatty acylation of proteins: new insights into membrane targeting of myrisoylated and palmitoylated proteins. Biochim. Biophys. Acta. 1999, 1451, 1-16.
152. Sterling, D.; Reithmeier RAF, Casey, J.R. A transport metabolon. J. Biol. Chem. 2001, 276, 47886-47894.
153. Soleimani, M.; Greeley, T.; Petrovic, S.; et al. Pendrin: an apical Cl-/OH-/HCO3-exchanger in kidney cortex. Am. J. Physiol. Renal. Physiol. 2001, 280, F356-F364.
154. Simonnet, H.; Demont, J.; Pfeiffer, K.; et al. Mitochondrial complex I is deficient in renal oncocytomas. Carcinogenesis. 2003, 24, 1461-1466.
155. Esteitie, N.; Hinttala, R.; Wilbom, R.; et al. Secondary metabolic effects in complex I deficiency. Ann. Neurol. 2005, 58, 544-552.
156. Eng, C.; Kiuuru, M.; Fernandez, M.J.; Aaltonen, L.A. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nature Rev. Cancer. 2003, 3, 193-202.
157. Cook, J.D.; Walker, C.L. The Eker rat: establishing a genetic paradigm linking renal cell carcinoma and uterine leiomyoma. Curr. Mol. Med. 2004, 4, 813-824.
158. Schmidt, L.S.; Warren, M.B.; Nickerson, M.L. et al. Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasis, maps to chromosome 17 p11.2 Am. J. Human Genet. 2001, 69, 876-882.
159. Haraguchi, S.; Fukuda, Y. Histogenesis of abnormal elastic fibers in blebs and bullae of patients with spontaneous pneumothorax: ultrastructural and immunohistochemical studies. Acta. Pathol. Jpn. 1993, 43, 709-722.
160. Taki, K.; Endo, S.; Hirahara, K.; Haano, K.; Totoki, T. Prevention by ulinastatin of decreased carbonic anhydrase activity induced by PMN elastase in vitro. Clin. Ther. 1994, 16, 263-270.
161. Bui, M.H.; Seligson, D.; Han, K.R.; et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 2003, 9, 802-811.
162. Atkins, M.; Regan, M.; McDermott, D.; et al. Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin. Cancer Res. 2005, 11, 3714-3721.
163. Raval, R.R.; Lau, K.W.; Tran, M.G.B.; et al. Contrasting properties of hypoxia inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau associated renal cell carcinoma. Mol. Cell Biol. 2005, 25, 5675-5686.